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Objectives: Brain metastases (BMs) often advance the course of non-small cell lung cancer 
(NSCLC). We performed an observational study in order to investigate the possible correlation 
of selected clinical and epidemiological factors with BM appearance in patients suffering from 
different histological subtypes of NSCLC stage I–IV .
Methods: The study included 161 consecutive patients with NSCLC. Analyzed data included 
patient- and tumor-related characteristics.
Results: Thirty-nine patients (24.2%) presented BMs within 12 (0–36) weeks of diagnosis. 
BMs decreased the mean overall survival significantly (15.6 versus 50.7 weeks, P , 0.001), 
with hazard ratio (95% confidence interval) 3.60 (2.42–5.35). The age of the patients with BM 
was significantly lower than that of the patients without BM (60.8 ± 8.9 versus 66.5 ± 8.5, 
P , 0.001). Patients with BM had significantly higher pack-years consumption (75.9 ± 23.9 
versus 58.9 ± 31.9, P = 0.003) and larger tumor size compared with patients without BM (size 
in mm: 55.1 ± 20.1 versus 45.9 ± 19.3, P = 0.012). The presence of BM was also correlated with 
the absence of lung (P , 0.001), bone (P = 0.005), and adrenal (P = 0.046) metastases.
Conclusion: Younger NSCLC patients with high tobacco consumption, large tumor size, and 
absence of metastases in other organs (lung, bones, adrenal metastases) are at high risk of BM 
appearance during the course of NSCLC and are candidates for prophylactic cranial irradiation 
early in the course of the disease.
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Introduction
Lung cancer was the leading cause of death from cancer in Europe in 2006, with 334,800 
deaths (19.7% of total).1 Non-small cell lung cancer (NSCLC) is the most common 
type of lung cancer, representing more than 80% of lung cancer cases.2
Brain metastases (BMs) are a frequent complication of NSCLC, especially in 
patients with locally advanced disease.3,4 The addition of chemotherapy to   radiation 
therapy (RT) reduces distant metastases and significantly improves survival.5,6   However, 
chemoradiotherapy is shown not to reduce the rate of BM,5 but to be associated with 
increased rates of overall brain failure (21%–54%) and an increased incidence of the 
brain as the first site of relapse (15%–30%).5–8 These findings emphasize the need for 
treatment specifically directed at brain micrometastases.
Prophylactic cranial irradiation (PCI) has been demonstrated to reduce the 
incidence or delay the onset of BM in patients with locally advanced NSCLC, after 
initial   treatment in numerous selected nonrandomized and randomized studies.3,7,9–16 
Nevertheless, during the last decade only few studies assessed the clinical and Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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epidemiological factors associated with high risk of BM 
appearance in NSCLC patients with locally advanced   disease 
at diagnosis.14,17–20 In these studies, several factors such as 
duration of survival after diagnosis, performance status, 
chemotherapy regimens, age at diagnosis, sex, and lung 
cancer histotype and stage have been associated with the 
risk of BM development.
The authors of this paper hypothesized that among 
NSCLC patients of stage I–IV may exist a group of patients 
at high risk of presenting BM that may be protected using 
PCI. This group should be identified in order to serve as target 
for future studies of PCI application in NSCLC.
We performed an observational study in order to 
investigate the possible correlation of selected clinical and 
epidemiological factors with BM appearance in patients 
suffering from different histological subtypes of NSCLC 
stage I–IV .
Methods
The study’s cohort
We recruited 161 consecutive patients with a new diagnosis 
of NSCLC, between January 2003 and March 2009. Patients’ 
selection criteria were as follows: confirmed diagnosis of 
NSCLC and appropriate staging. The sixth edition of the 
tumor–node–metastasis (TNM) classification was used.21
All patients were treated with surgery and/or   chemotherapy 
and/or radiotherapy according to the current guidelines.22,23 
They were evaluated every 3–6 months, depending on the 
curative or palliative nature of the initial treatment.
For each patient, the following variables were recorded 
at the time of diagnosis: age, sex, tobacco consumption, 
comorbidities, TNM status at diagnosis, tumor histotype, 
computed tomography (CT) scan features (central/peripheral 
location, side, lung lobe, size, cavitation, pleural effusion), and 
bronchoscopic findings. During the study period, the variables 
of patients with BM were registered and compared with those 
of patients without BM. All patients gave their informed 
consent, and the study was approved by the Ethics Committee 
of the “Sotiria” Chest Diseases Hospital, Athens.
statistical analysis
Mean values (and standard deviation [SD]) or median 
values (and interquartile range [IR]) were used to describe 
quantitative variables. For the comparison of quantitative 
variables without normal distribution between two groups, 
and between three or more different groups, the Mann–
Whitney test and Kruskal–Wallis test were used, respectively. 
To compare normal distributed quantitative variables 
between two groups and between three or more different 
groups, Student’s t-test and analysis of variance test were 
used, respectively.
To control for type I errors, due to multiple comparisons, 
Bonferroni correction was used, by which the significance 
level is defined as 0.05/k (k = number of comparisons). 
Logistic regression analysis (stepwise method) was used 
in order to find independent factors associated with BM 
presentation. Odds ratios (ORs) and 95% confidence intervals 
(CIs) were computed from the results of logistic analysis. 
Kaplan–Meyer method was used to estimate survival curves. 
To compare survival curves, log rank tests were used. 
Statistical significance was set at 0.05, and all P-values are 
two tailed. For the statistical analysis, SPSS Statistics 17.0 
(IBM Corporation, Somers, NY) and STATA 9.0 (Stata Corp, 
College Station, TX) programs were used.
Results
Description of the cohort
Patient’s characteristics are summarized in Table 1. Most 
of the patients were males (88.8%), with mean age (±SD) 
65.1 ± 8.9 years and mean tobacco consumption (±SD) of 
63.0 ± 31.0 pack-years.
Most of the tumors were located centrally (85.7%). 
Therefore, they were located within the range of fiber 
bronchoscopy, which revealed mainly mucosal or submucosal 
infiltration (67.7%). Most of the tumors were on the right 
lung (52.2%) and on the upper lobes (70.2%). The mean 
size (±SD) of the tumors, measured on CT scanners, was 
48.1 ± 19.8 mm. Almost one-third (36.6%) were accompa-
nied by pleural effusion at presentation. During the disease 
course, 37.3% of the patients presented lung, 36.6% bone, 
23% liver, and 21.7% adrenal metastases.
BMs
BMs were presented in 24.2% of the patients. The median 
time (IR) of BM appearance was 12 (0–36) weeks from 
  diagnosis. At the time of BM presentation, most of the 
patients were classified as T4 (42.9%) and N2 (43.5%) by 
the TNM classification. A total of 59% of the BMs were $2, 
mostly unilateral (53.8%).
The overall survival of the cohort was influenced by the 
presence of BM (Figure 1). Survival time of the patients 
with BM was shorter compared with those without BM: 
15.6 weeks (standard error [SE] = 1.9) versus 50.7 weeks 
(SE = 4.8, P , 0.001). The hazard ratio, upon Cox model, 
for the presence of BM was 3.60 (95% CI 2.42–5.35, 
P , 0.001).Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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The age of patients with BM was significantly lower 
compared with that of the patients without BM (60.8 ± 8.9 
versus 66.5 ± 8.5, P , 0.001) (Table 2). Furthermore, 
patients with BM had significantly higher pack-years con-
sumption (75.9 ± 23.9 versus 58.9 ± 31.9, P = 0.003) and 
larger tumor size compared with patients without BM (size 
in mm: 55.1 ± 20.1 versus 45.9 ± 19.3, P = 0.012). The 
presence of BM was also correlated with the absence of 
lung (P , 0.001), bone (P = 0.005), and adrenal (P = 0.046) 
metastases.
Patients with right-sided BM presented a significantly 
lower rate of arterial hypertension (16.7% versus 83.8%, 
P = 0.050) (Table 3). None of the patients with unilobar 
BM suffered from diabetes, compared with patients with 
multilobar ($2 lobes) metastases (P = 0.015) (Table 4).
According to regression analysis, age, tobacco consump-
tion in pack-years, and absence of lung or bone metastases 
represented independent prognostic factors for the appear-
ance of BM (Table 5). In particular, an increase of age 
reduced the possibility of BM appearance (OR 0.91; 95% 
CI 0.87–0.96, P , 0.001). Conversely, increasing cigarette 
consumption increased the possibility of BM appearance (OR 
1.02; 95% CI 1.001–1.030, P = 0.006). Patients without lung 
Table 1 Patient- and disease-related characteristics
Characteristic n (%)
Patient-related variables
sex
Male/female 143 (88.8)/18 (11.2)
Age
Mean ± sD 65.1 ± 8.9
Pack-years
Mean ± sD 63.0 ± 31.0
COPD
no/yes 89 (55.3)/72 (44.7)
Arterial hypertension
no/yes 98 (60.9)/63 (39.1)
Coronary disease
no/yes 132 (82.0)/29 (18.0)
Diabetes mellitus
no/yes 136 (84.5)/25 (15.5)
gastritis/ulcer
no/yes 138 (85.7)/23 (14.3)
hypothyroidism
no/yes 154 (95.7)/7 (4.3)
Other comorbidity
no/yes 130 (80.7)/31 (19.3)
Disease-related variables
histotype
non-differentiated  
nsCLC
49 (30.4)
squamous 49 (30.4)
Adenocarcinoma 59 (36.6)
Large cell carcinoma 4 (2.6)
Location
Central/peripheral 138 (85.7)/23 (14.3)
Bronchoscopic findings
Mass 36 (22.4)
Infiltration 109 (67.7)
none 16 (9.9)
Lung tumor side
Right/left 84 (52.2)/77 (47.8)
Lung tumor lobe
Upper 113 (70.2)
Middle 8 (5.0)
inferior 40 (24.8)
Lung tumor size
Mean ± sD 48.1 ± 19.8
Other tumor  
characteristics
Pleural effusion 59 (36.6)
Cavitation 12 (7.5)
none 90 (55.9)
T classification  
(brain metastases)a
T1/T2 13 (8.1)/55 (34.2)
T3/T4 24 (14.9)/69 (42.9)
N classification  
(brain metastases)a
n0/n1 38 (23.6)/16 (9.9)
n2/n3 70 (43.5)/37 (23.0)
Lung metastasis
no/yes 101 (62.7)/60 (37.3)
Bones metastasis
no/yes 102 (63.4)/59 (36.6)
(Continued)
Table 1 (Continued)
Characteristic n (%)
Liver metastasis
no/yes 124 (77.0)/37 (23.0)
Adrenal metastasis
no/yes 126 (78.3)/35 (21.7)
Other metastasis
no/yes 144 (89.4)/17 (10.6)
Metastasis brain
no/yes 122 (75.8)/39 (24.2)
Diagnosis to brain  
metastases time (weeks)
Median (iR) 12 (0–36)
number of brain  
metastases
0/1 122 (75.8)/16 (9.9)
2/.2 6 (3.7)/17 (10.6)
Brain metastasis side
Right 12 (30.8)
Left 9 (23.0)
Bilateral 18 (46.2)
Brain metastasis lobe
Frontal 9 (23.1)
Parietal 9 (23.1)
Occipital 1 (2.6)
Cerebellum 2 (5.1)
$2 18 (46.2)
Note: aTNM (tumor–node–metastasis) classification.21
Abbreviations: COPD, chronic obstructive pulmonary disease; iR, interquartile 
range; nsCLC, non-small cell lung cancer; sD, standard deviation.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Figure 1 Kaplan–Meier estimation of overall survival (patients with or without brain metastases). 
Abbreviation: meta, metastasis.
and bone metastases had 76% and 70% higher possibility of 
presenting BM, respectively.
Discussion
The main finding of this observational study was that 
younger NSCLC patients with high tobacco consumption, 
large tumor size, and absence of other metastases are at high 
risk of developing BMs during the course of their disease.
BM appearance and survival
Robnett et al reported that the timing of chest irradiation 
can influence the risk of brain recurrences: the rate of BM 
is 27% in patients receiving induction chemotherapy before 
thoracic RT compared with 15% in patients who are treated 
with concurrent chemoradiation.17 The 2-year actuarial rate 
of BM is 39% versus 20%. The authors hypothesize that 
early aggressive locoregional and systemic treatment could 
better control regional disease, which in turn affects the 
development of brain relapses. In accordance with these 
findings, BMs presented in 39 out of 161 patients (24.2%) 
in this present study. The rate of BM is quite similar to the 
rate which has been previously reported by Robnett et al 
for patients who were not treated with concurrent chemo-
radiotherapy. The lack of a radiotherapy department in the 
“Sotiria” Chest Diseases Hospital renders impossible the 
application of concurrent chemoradiotherapy and therefore 
leads to the application of the sequential module.
Once diagnosed, BMs are mostly treated with whole-
brain radiotherapy, having a response rate of 45%–81% in 
NSCLC.24,25 The overall survival of NSCLC patients with 
BM is poor, reported to be 3–6 months, despite medical 
treatment.26 The overall survival of the patients in this present 
study with BM was also poor, approximately 4 months.
Patients who are at high risk  
of developing BM
The delay of BM appearance is expected to improve prog-
nosis of NSCLC patients. To achieve this, we need objec-
tive means to indicate patients at high risk for developing 
BM. Some studies have already been oriented towards this 
direction. Biologic agents like neuron specific enolase, car-
cinoembryonic antigen, serum sodium levels, or numerous 
molecular markers have been correlated with the develop-
ment of BM and a shorter survival.26–28
Nevertheless, specific phenotypic characteristics may also 
serve as surrogate prognostic factors. Earlier studies correlated 
the presence of BM with advanced stage, NSCLC histotypes, 
delay of lung radiotherapy, younger age, and large tumor 
size.28–32 However, few studies assessed in this regard tobacco 
consumption, comorbidities, CT scanner tumor characteris-
tics, or the presence of metastases other than BMs.
Age at diagnosis
Age , 60 years was shown to be associated with an 
increased risk of BM.30,33,34 In this present study, younger age 
(60.8 ± 8.9 years) was correlated with a higher possibility of 
BM appearance (Table 2). However, younger patients with BM 
present a better performance status and longer survival, while 
they may tolerate aggressive treatment better and are willing 
to accept a higher risk of toxicity than older patients.26,35Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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T and n status
T4 initial status was associated with increased risk of BM in a 
multivariate analysis of 305 patients with localized NSCLC.30 
The N2 status was found to be predictive of BM by Jacobs 
et al and by Tang et al.36,37
In this study, lung tumor size was correlated with the 
appearance of BM (55.1 ± 20.1 cm) (Table 2). This finding is 
in agreement with the study of Mujoomdar et al.31 However, 
no correlation was found with the T status itself. T status, 
as well as N status, has been correlated with BM outbreak 
in recent studies.30,31
As is the case in the study of Shi et al, the authors of this 
present study found most of the primary tumors to be located 
in the right lung and in the upper lobes.32 These frequent 
locations of lung tumor did not seem to correlate with the 
appearance of BM.32 Central or peripheral location of primary 
lung tumor was not found to be correlated to BM, which is 
in agreement with the study of Mujoomdar et al.31
M status
Previous studies speculate that the spread of lung cancer to the 
thoracic lymphatic system and to the brain could also relate to 
the presence of distant metastatic disease in other organs.31 So 
far, no study has confirmed this hypothesis. On the contrary, in 
this present study, appearance of BM was correlated with the 
absence of metastases in other organs, like lung, bone, and adre-
nal glands. Except adrenal metastases,27 synchronous metastases 
in other organs have not been correlated with median survival, 
probably as a result of already poor prognosis of the BM.26
Tobacco consumption
Smoking status has already been correlated with poor 
prognosis and shorter overall survival in lung cancer 
patients,18 but no correlation was found with BM. In this 
study’s cohort, high tobacco consumption (75.9 ± 23.9 pack-
years) was correlated with the outbreak of BM.
Table  2  Correlation  of  brain  metastases  with  patient-  and 
disease-related features (univariate analysis)
Feature Brain metastases P χ² test
No (N) Yes (N)
Patient-related variables
sex
Male/female 108/14 35/4 0.833
Age
Mean ± sD 66.5 ± 8.5 60.8 ± 8.9 ,0.001a
Pack-years
Mean ± sD 58.9 ± 31.9 75.9 ± 23.9 0.003a
COPD
no/yes 68/54 21/18 0.836
Arterial hypertension
no/yes 77/45 21/18 0.302
Diabetes mellitus
no/yes 102/20 34/5 0.592
Coronary disease
no/yes 98/24 34/5 0.332
hypothyroidism
no/yes 118/4 36/3 0.361b
gastritis/ulcer
no/yes 105/17 33/6 0.822
Other comorbidity
no/yes 97/25 33/6 0.481
Disease-related variables
histotype
non-differentiated nsCLC 33 16 0.586b
squamous 38 11
Adenocarcinoma 48 11
Large cell carcinoma 3 1
Location
Central/peripheral 105/17 33/6 0.822
Bronchoscopic findings
Mass 29 7 0.151
Infiltration 78 31
none 15 1
Lung tumor side
Right/left 62/60 22/17 0.543
Lung tumor lobe
Upper 86 27 0.657
Middle 5 3
inferior 31 9
Lung tumor size
Mean ± sD 45.9 ± 19.3 55.1 ± 20.1 0.012a
Other tumor characteristics
Pleural effusion 48 11 0.399
Cavitation 8 4
none 66 24
T classification (brain metastases)c
T1/T2 10/37 3/18 0.138
T3/T4 22/53 2/16
N classification (brain metastases)c
n0/n1 29/10 9/6 0.550
n2/n3 53/30 17/7
Lung metastasis
no/yes 67/55 34/5 ,0.001
(Continued)
Table 2 (Continued)
Feature Brain metastases P χ² test
No (N) Yes (N)
Bone metastasis 
no/yes 70/52 32/7 0.005
Liver metastasis
no/yes 91/31 33/6 0.195
Adrenal
no/yes 91/31 35/4 0.046
Other metastasis
no/yes 107/15 37/2 0.205
Notes:  astudent’s  t-test;  bFisher’s  exact  test;  cTnM  (tumor–node–metastasis) 
classification.21
Abbreviations: COPD, chronic obstructive pulmonary disease; nsCLC, non-small 
cell lung cancer; sD, standard deviation.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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nsCLC histological subtype
In previous studies, non-squamous lung cancer, mainly 
lung adenocarcinoma, showed higher prevalence of BM 
development.30–32 In this study, no correlation was found 
between NSCLC histotype and BM appearance. This discor-
dance is probably a result of the small number of allocated 
groups and the relatively large number of unspecified NSCLC 
tumors in the present study.
PCi
Prophylactic cranial irradiation (PCI) has been demon-
strated to reduce the incidence or delay the onset of BM 
in patients with locally advanced NSCLC after initial 
treatment.3,7,9–16 Thus, identification of risk population 
for BM development is pertinent. Specific phenotypes of 
patients at higher risk for BM development could serve 
as candidates of PCI and could allow early interven-
tion, which seems more promising than the palliative 
approach.
Limitations
The patients in this current study were treated with sequential 
rather than concurrent chemoradiotherapy despite the current 
treatment guidelines. This limitation of the study is due to 
the lack of a radiotherapy department in the “Sotiria” Chest 
Diseases Hospital.
The pathologic data lack molecular markers, which 
could be related to the overall survival as is the case in many 
Table 3 Univariate analysis of brain metastases side
Metastasis side P χ² test
Right  
(N)
Left  
(N)
Bilateral  
(N)
Patient-related variables
sex
Male/female 11/1 9/0 15/3 0.546
Age
Mean ± sD 57.7 ± 8.3 62.6 ± 9.9 61.9 ± 8.7 0.349a
Pack-years
Mean ± sD 80.8 ± 20.2 84.0 ± 19.6 68.6 ± 26.8 0.202a
COPD
no/yes 6/6 5/4 10/8 1.000
Arterial hypertension
no/yes 10/2 4/5 7/11 0.050
Coronary disease
no/yes 12/0 9/0 13/5 0.054
Diabetes mellitus
no/yes 11/1 9/0 14/4 0.406
gastritis/ulcer
no/yes 12/0 7/2 17/1 0.216
hypothyroidism
no/yes 12/0 6/3 15/3 0.063
Other comorbidity
no/yes 11/1 7/2 15/3 0.740
Disease-related variables
histotype
non-differentiated  
nsCLC
6 2 7 0.194
squamous 2 4 5
Adenocarcinoma 3 3 6
Large cell  
carcinoma
1 0 0
Location
Central/peripheral 10/2 8/1 15/3 1.000
Diagnosis to brain metastases time (weeks)
Median (iR) 18 (4–40) 0 (0–26) 14 (0–36) 0.632b
Notes: aAnalysis of variance; bKruskall–Wallis test.
Abbreviations: COPD, chronic obstructive pulmonary disease; iR, interquartile 
range; nsCLC, non-small cell lung cancer; sD, standard deviation.
Table 4 Univariate analysis of brain metastases lobes
  Metastasis lobe P Fisher’s  
exact test 1 lobe  
(N)
$2 lobes  
(N)
Patient-related variables
sex
Male/female 19/2 16/2 1.000
Age
Mean ± sD 61.0 ± 9.5 60.6 ± 8.3 0.891a
Pack-years
Mean ± sD 79.1 ± 19.8 72.2 ± 28.0 0.377a
COPD
no/yes 12/9 9/9 0.656b
Arterial hypertension
no/yes 13/8 8/10 0.276b
Diabetes mellitus
no/yes 21/0 13/5 0.015
Coronary disease
no/yes 20/1 14/4 0.104
hypothyroidism
no/yes 19/2 17/1 1.000
gastritis/ulcer
no/yes 18/3 15/3 1.000
Other comorbidity
no/yes 17/4 16/2 0.667
Disease-related variables
histotype
non-differentiated  
nsCLC
7 8 0.088
squamous 5 6
Adenocarcinoma 8 4
Large cell carcinoma 1 0
Location
Central/peripheral 17/4 16/2 0.667
Diagnosis to brain metastases time (weeks)
Median (iR) 17 (0–32) 8 (0–36) 0.922c
Notes: astudent’s t-test; bPearson’s χ2 test; cMann–Whitney test.
Abbreviations: COPD, chronic obstructive pulmonary disease; iR, interquartile 
range; nsCLC, non-small cell lung cancer; sD, standard deviation.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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recent studies. In fact, during the study period, molecular 
data were not available.
implications
This study records the deleterious effect of BMs on NSCLC 
patient survival, enriches the high risk profile with more fea-
tures, and contributes to the discussion of pathophysiologic 
mechanisms underlying the brain involvement in NSCLC. 
More studies are needed in order to elucidate these issues.
Conclusion
Younger NSCLC patients with high tobacco consumption, 
large tumor size, and absence of other metastases (lung, 
bones, adrenal metastases) are at high risk of BM appearance 
during the course of NSCLC and may be candidates for PCI 
early in the course of their disease. Apart from genome-based 
studies, phenotype-based studies may contribute to future 
lung cancer therapy.
Disclosure
The authors report no conflicts of interest in this work.
References
1.  Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P.   Estimates 
of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 
2007;18:581–592.
2.  Walker S. Updates in non-small cell lung cancer. Clin J Oncol Nurs. 
2008;2:587–596.
3.  Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide 
plus chest radiotherapy followed by surgery for stages IIIA (N2) and 
IIIB non-small-cell lung cancer: Mature results of Southwest Oncology 
Group Phase II study 8805. J Clin Oncol. 1995;13:1880–1892.
4.  Andre F, Grunenwald D, Pujol JL, et al. Patterns of relapse of N2 
nonsmall-cell lung carcinoma patients treated with preoperative che-
motherapy: Should prophylactic cranial irradiation be reconsidered? 
Cancer. 2001;91:2394–2400.
5.  Cox JD, Scott CB, Byhardt RW, et al. Addition of chemotherapy to 
radiation therapy alters failure patterns by cell type within non-small cell 
carcinoma of lung (NSCCL): Analysis of Radiation Therapy Oncology 
Group (RTOG) trials. Int J Radiat Oncol Biol Phys. 1999;43:505–509.
6.  Cooper JD, Silverman S, Clement JA. Prophylactic cranial irradiation for 
lung cancer patients at high risk for development of cerebral metastasis: 
Results of a prospective randomized trial conducted by the Radiation Ther-
apy Oncology Group. Int J Radiat Oncol Biol Phys. 1991;21:637–643.
  7.  Stuschke M, Eberhardt W, Pottgen C, et al. Prophylactic cranial irradia-
tion in locally advanced nonsmall-cell lung cancer after multimodality 
treatment: Long-term follow-up and investigations of late neuropsy-
chologic effects. J Clin Oncol. 1999;17:2700–2709.
  8.  Andre F, Grunenwald D, Pujol JL, et al. Patterns of relapse of N2 
nonsmall-cell lung carcinoma patients treated with preoperative che-
motherapy: Should prophylactic cranial irradiation be reconsidered? 
Cancer. 2001;91:2394–2400.
  9.  Strauss GM, Herndon JE, Sherman DD, et al. Neoadjuvant chemo-
therapy and radiotherapy followed by surgery in stage IIIA non-small 
cell carcinoma of the lung: Report of a Cancer and Leukemia Group B 
phase II study. J Clin Oncol. 1992;10:237–1244.
  10.  Rusch VW, Griffin BR, Livingston RB. The role of prophylactic 
cranial irradiation in regionally advanced non-small cell lung cancer. 
A Southwest Oncology Group Study. J Thorac Cardiovasc Surg. 
1989;98:535–539.
  11.  Skarin A, Jochelson M, Sheldon T, et al. Neoadjuvant chemotherapy in 
marginally resectable stage III M0 non-small cell lung cancer: Longterm 
follow-up in 41 patients. J Surg Oncol. 1989;40:266–274.
  12.  Russell AH, Pajak TE, Selim HM, et al. Prophylactic cranial irradia-
tion for lung cancer patients at high risk for development of cerebral 
metastasis: Results of a prospective randomized trial conducted by the 
Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 
1991;21:637–643.
  13.  Umsawasdi T, Valdivieso M, Chen TT, et al. Role of elective brain 
irradiation during combined chemoradiotherapy for limited disease 
non-small cell lung cancer. J Neuro Oncol. 1984;2:253–259.
  14.  Cox JD, Stanley K, Petrovich Z, Paig C, Yesner R. Cranial irradiation 
in cancer of the lung of all cell types. JAMA. 1981;245:469–472.
  15.  Pöttgen C, Eberhardt W, Grannass A, et al. Prophylactic cranial irra-
diation in operable stage IIIA non-small-cell lung cancer treated with 
neoadjuvant chemoradiotherapy: Results from a German multicenter 
trial. J Clin Oncol. 2007;25:4987–4992.
  16.  Yavuz AA, Topkan E, Onal C, Yavuz MN. Prophylactic cranial irra-
diation in locally advanced non-small cell lung cancer: Outcome of 
recursive partitioning analysis group I patients. J Exp Clin Cancer Res. 
2008;27:80.
  17.  Robnett TJ, Machtay M, Stevenson JP, Algazy KM, Hahn SM. Factors 
affecting the risk of brain metastases after definitive chemoradiation 
for locally advanced non-small-cell lung carcinoma. J Clin Oncol. 
2001;19:1344–1349.
  18.  Law A, Karp DD, Dipetrillo T, Daly BT. Emergence of increased 
cerebral metastasis after high-dose preoperative radiotherapy with 
chemotherapy in patients with locally advanced non-small cell lung 
carcinoma. Cancer. 2001;92:160–164.
  19.  Ceresoli GL, Reni M, Chiesa G, et al. Brain metastases in locally 
advanced nonsmall cell lung carcinoma after multimodality treatment: 
Risk factors analysis. Cancer. 2002;95:605–612.
  20.  Carolan H, Sun AY, Bezjak A, et al. Does the incidence and outcome 
of brain metastases in locally advanced non-small cell lung cancer 
justify prophylactic cranial irradiation or early detection? Lung Cancer. 
2005;49:109–115.
  21.  Sobin LH, Wittekind C; and the International Union Against Cancer 
(UICC), editors. TNM Classification of Malignant Tumors. 6th ed. New 
York, NY: Wiley-Liss; 2002:99–103.
  22.  Alberts M. Lung Cancer Guidelines. Chest. 2003;123:1–2.
  23.  Alberts M. Diagnosis and management of lung cancer. Executive 
  summary. Chest. 2007;132:1–19.
  24.  Addeo R, Caraglia M, Faiola V, et al. Concomitant treatment of brain 
metastasis with whole brain radiotherapy [WBRT] and temozolomide 
[TMZ] is active and improves quality of life. BMC. 2007;7:18.
  25.  Ma S, Xu Y, Deng Q, Yu X. Treatment of brain metastasis from non-
small cell lung cancer with whole brain radiotherapy and Gefitinib in 
a Chinese population. Lung Cancer. 2009;65:198–203.
  26.  Jacot W, Quantin X, Boher JM, et al. Brain metastases at the time of 
presentation of non-small cell lung cancer: A multi-centric AERIO* 
analysis of prognostic factors. Br J Cancer. 2001;84:903–909.
Table  5  Correlation  of  brain  metastases  with  patient-  and 
disease-related features (multivariate analysis)
Variable Odds ratio 95%  CI P
Age 0.91 0.87 0.96 ,0.001
Pack-years 1.02 1.01 1.03 0.006
Lung metastasis
no 1.00a
Yes 0.24 0.08 0.69 0.008
Bone metastasis
no 1.00a
Yes 0.30 0.11 0.81 0.018
Note: aRepresents referral class.Cancer Management and Research
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/cancer-management-and-research-journal
Cancer Management and Research is an international, peer-reviewed 
open access journal focusing on cancer research and the optimal use of 
preventative and integrated treatment interventions to achieve improved 
outcomes, enhanced survival and quality of life for the cancer patient. 
The journal welcomes original research, clinical & epidemiological 
studies, reviews & evaluations, guidelines, expert opinion & commen-
tary, case reports & extended reports. The manuscript management 
system is completely online and includes a very quick and fair peer-
review system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
294
Dimitropoulos et al
  27.  Penel N, Brichet A, Prevost B, et al. Prognostic factors for synchronous 
brain metastases from lung cancer. Lung Cancer. 2001;33:143–154.
  28.  Arrieta O, Saavedra-Perez D, Kuri R, et al. Brain metastasis develop-
ment and poor survival associated with carcinoembryonic antigen 
(CEA) level in advanced non-small cell cancer: A prospective analysis. 
BMC Cancer. 2009;9:119.
  29.  Robnett T, Machtay M, Stevenson J, et al. Factors affecting the risk of 
brain metastases after definitive chemoradiation for locally advanced 
non-small-cell lung carcinoma. J Clin Oncol. 2001;19:1344–1349.
  30.  Bajard A, Westeel V , Dubiez A. Multivariate analysis of factors pre-
dictive of brain metastases in localized non-small cell lung carcinoma. 
Lung Cancer. 2004;45:317–323.
  31.  Mujoomdar A, Austin J, Malhota R, et al. Clinical predictors of 
metastatic disease to the brain from non-small cell lung carcinoma: 
Primary tumor size, cell type, and lymph node metastases. Radiology. 
2007;242:882–888.
  32.  Shi A, Digumarthy S, Temel J, Halpern EF, Kuester LB, Aquino SL. 
Does initial staging or tumor histology better identify asymptomatic 
brain metastases in patients with non-small cell lung caner? J Thorac 
Oncol. 2006;1:205–210.
  33.  Ceresoli GL, Reni M, Chiesa G, et al. Brain metastases in locally 
advanced non-small cell lung carcinoma after multimodality treatment: 
Risk factors analysis. Cancer. 2002;95:605–612.
  34.  Schouten LJ, Rutten J, Huveneers HA, Twinjstra A. Incidence of brain 
metastases in a cohort of patients with carcinoma of the breast, colon, 
kidney, and lung and melanoma. Cancer. 2002;94:2698–2705.
  35.  Gore E. Brain metastases in very young patients with lung cancer are 
still brain metastases. Onkologie. 2008;31:297–268.
  36.  Jacobs RH, Awan A, Bitran JD, et al. Prophylactic cranial irradiation 
in adenocarcinoma of the lung: A possible role. Cancer. 1987;59: 
2016–2019.
  37.  Tang SG, Lin FJ, Leung VM. Impact of cranial irradiation in adeno-
carcinoma of the lung. J Formos Med Assoc. 1993;92:413–419.